Study #2024-0310
A phase 3, open-label, multicenter, randomized study of Tarlatamab in combination with Durvalumab vs Durvalumab alone in subjects with extensive-stage Small-Cell Lung cancer following platinum, Etoposide and Durvalumab (DeLLphi-305)
MD Anderson Study Status
Enrolling
Treatment Agent
Tarlatamab, Durvalumab
Description
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study phase:
Phase III
Physician name:
Carl Gay
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.